The first phase I trial of nivolumab, a PD-1 antibody, achieved only one complete response among 14 patients with mCRC and the case was a tumor with dMMR with PD-L1+ lymphocyte infiltration surrounding tumor cells [25]. Here, PDCD1 is linked to neoplasm.